AcuraStem and Takeda Partner to Revolutionize ALS Treatment

As of September 25, 2023, AcuraStem and Takeda have joined forces through a license agreement to propel the progress of PIKFYVE therapeutics. This partnership paves the way for the development of groundbreaking treatments, including AcuraStem’s very own AS-202 Candidate. AS-202 is an antisense oligonucleotide specifically designed to suppress the expression of PIKFYVE. Under this agreement, Takeda will be granted an exclusive, worldwide license to AcuraStem’s PIKFYVE program, while AcuraStem will receive substantial upfront and milestone payments, amounting to approximately $580M.